An atypical long-acting injectable antipsychotic: Implications for pharmacotherapy of schizophrenia

Journal of Psychopharmacology

Volumn 19, Issue 5 SUPPL., 2005, Pages 3-4

  Dursun, Serdar ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAVENOUS; RISPERIDONE; SCHIZOPHRENIA;

EID: 25844454528     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105057347     Document Type: Editorial

References (13)

1. Andreasen N C, Carpenter W T, Jr., Kane J M, Lasser R A, Marder S R, Weinberger D R (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441-449
2. Barnes TRE, McPhillips M A (1998) The role of medication in the re-integration of schizophrenia. In J A Lieberman (ed.), Re-integration of the Schizophrenic Patient. Science Press, London, pp. 21-34.
3. Chue P (2003) Risperidone long-acting injection. Expert Rev Neurotherapeutics 3: 435-446
4. Ereshefsky L, Mascarenas C A (2003) Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64 Suppl 16: 18-23
5. Fleischhacker W W, Eerdekens M, Karcher K, Remington G, Llorca P, Chrzanowski W, Martin S, Gefvert O (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257
6. Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, Remmerie B, Eerdekens M, Nyberg S (2005) Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Constatrade mark) in patients with schizophrenia. Int J Neuropsychopharmacol 8: 27-36
7. Kane J (2001) Progress defmed-short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 16 Suppl 1: S1-S8
8. Kane J M, Eerdekens M, Lindenmayer J P, Keith S J, Lesem M, Karcher K (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132
9. Leucht S, Barnes T R, Kissling W, Engel R R, Correll C, Kane J M (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209-1222
10. Marder S R (2003) Overview of partial compliance. J Clin Psychiatry 64 Suppl 16: 3-9
11. Müller N (2004) Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 37 Suppl 2: S141-S147
12. NICE (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Health Technology Appraisal No. 43. National Institute for Clinical Excellence, London
13. Ware J E, Jr., Sherbourne C D (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483